Targeting Axl with an high-affinity inhibitory aptamer

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2291-2303

  Cerchia, Laura ^a   Esposito, Carla L ^a   Camorani, Simona ^a,b   Rienzo, Anna ^a   Stasio, Loredana ^c   Insabato, Luigi ^c   Affuso, Andrea ^d,e   De Franciscis, Vittorio ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Istituto di Ricerche Genetiche Gaetano Salvatore Biogem sc arl   (Italy)

^e STAZIONE ZOOLOGICA ANTON DOHRN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; AXL PROTEIN; GL21 T APTAMER; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CELL TRANSFORMATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

MUS;

EID: 84870615894     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.163     Document Type: Article

References (50)

1. Ohashi, K, Nagata, K, Toshima, J, Nakano, T, Arita, H, Tsuda, H et al. (1995). Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. J Biol Chem 270: 22681-22684.
2. Stitt, TN, Conn, G, Gore, M, Lai, C, Bruno, J, Radziejewski, C et al. (1995). The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80: 661-670.
3. Varnum, BC, Young, C, Elliott, G, Garcia, A, Bartley, TD, Fridell, YW et al. (1995). Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373: 623-626.
4. Mark, MR, Chen, J, Hammonds, RG, Sadick, M and Godowsk, PJ (1996). Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 271: 9785-9789.
5. Hall, MO, Obin, MS, Heeb, MJ, Burgess, BL and Abrams, TA (2005). Both protein S and Gas6 stimulate outer segment phagocytosis by cultured rat retinal pigment epithelial cells. Exp Eye Res 81: 581-591.
6. Uehara, H and Shacter, E (2008). Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J Immunol 180: 2522-2530.
7. Prasad, D, Rothlin, CV, Burrola, P, Burstyn-Cohen, T, Lu, Q, Garcia de Frutos, P et al. (2006). TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 33: 96-108.
8. Shieh, YS, Lai, CY, Kao, YR, Shiah, SG, Chu, YW, Lee, HS et al. (2005). Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-1064.
9. Sainaghi, PP, Castello, L, Bergamasco, L, Galletti, M, Bellosta, P and Avanzi, GC (2005). Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204: 36-44.
10. Zhang, YX, Knyazev, PG, Cheburkin, YV, Sharma, K, Knyazev, YP, Orfi, L et al. (2008). AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68: 1905-1915.
11. Wu, CW, Li, AF, Chi, CW, Lai, CH, Huang, CL, Lo, SS et al. (2002). Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 22(2B): 1071-1078.
12. Koorstra, JB, Karikari, CA, Feldmann, G, Bisht, S, Rojas, PL, Offerhaus, GJ et al. (2009). The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8: 618-626.
13. Chung, BI, Malkowicz, SB, Nguyen, TB, Libertino, JA and McGarvey, TW (2003). Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 22: 533-540.
14. Hutterer, M, Knyazev, P, Abate, A, Reschke, M, Maier, H, Stefanova, N et al. (2008). Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14: 130-138.
15. Rikova, K, Guo, A, Zeng, Q, Possemato, A, Yu, J, Haack, H et al. (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
16. Avilla, E, Guarino, V, Visciano, C, Liotti, F, Svelto, M, Krishnamoorthy, G et al. (2011). Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 71: 1792-1804.
17. Sensi, M, Catani, M, Castellano, G, Nicolini, G, Alciato, F, Tragni, G et al. (2011). Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol 131: 2448-2457.
18. Ghosh, AK, Secreto, C, Boysen, J, Sassoon, T, Shanafelt, TD, Mukhopadhyay, D et al. (2011). The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 117: 1928-1937.
19. Hong, CC, Lay, JD, Huang, JS, Cheng, AL, Tang, JL, Lin, MT et al. (2008). Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268: 314-324.
20. Liu, L, Greger, J, Shi, H, Liu, Y, Greshock, J, Annan, R et al. (2009). Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69: 6871-6878.
21. Sayan, AE, Stanford, R, Vickery, R, Grigorenko, E, Diesch, J, Kulbicki, K et al. (2012). Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene 31: 1493-1503.
22. Xu, MZ, Chan, SW, Liu, AM, Wong, KF, Fan, ST, Chen, J et al. (2011). AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30: 1229-1240.
23. Linger, RM, Keating, AK, Earp, HS and Graham, DK (2008). TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83.
24. Verma, A, Warner, SL, Vankayalapati, H, Bearss, DJ and Sharma, S (2011). Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10: 1763-1773.
25. Holland, SJ, Pan, A, Franci, C, Hu, Y, Chang, B, Li, W et al. (2010). R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70: 1544-1554.
26. Ye, X, Li, Y, Stawicki, S, Couto, S, Eastham-Anderson, J, Kallop, D et al. (2010). An anti- Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29: 5254-5264.
27. Cerchia, L and de Franciscis, V (2011). Nucleic acid aptamers against protein kinases. Curr Med Chem 18: 4152-4158.
28. Esposito, CL, Catuogno, S, de Franciscis, V and Cerchia, L (2011). New insight into clinical development of nucleic acid aptamers. Discov Med 11: 487-496.
29. Cerchia, L and de Franciscis, V (2007). Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases. Methods Mol Biol 361: 187-200.
30. Cerchia, L and de Franciscis, V (2010). Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28: 517-525.
31. Cerchia, L, Esposito, CL, Jacobs, AH, Tavitian, B and de Franciscis, V (2009). Differential SELEX in human glioma cell lines. PLoS ONE 4: e7971.
32. Rockey, WM, Hernandez, FJ, Huang, SY, Cao, S, Howell, CA, Thomas, GS et al. (2011). Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther 21: 299-314.
33. Hanahan, D and Weinberg, RA (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
34. Braunger, J, Schleithoff, L, Schulz, AS, Kessler, H, Lammers, R, Ullrich, A et al. (1997). Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 14: 2619-2631.
35. Esposito, CL, Passaro, D, Longobardo, I, Condorelli, G, Marotta, P, Affuso, A et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6: e24071.
36. Fridell, YW, Villa, J Jr, Attar, EC and Liu, ET (1998). GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 273: 7123-7126.
37. Vajkoczy, P, Knyazev, P, Kunkel, A, Capelle, HH, Behrndt, S, von Tengg-Kobligk, H et al. (2006). Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103: 5799-5804.
38. Holland, SJ, Powell, MJ, Franci, C, Chan, EW, Friera, AM, Atchison, RE et al. (2005). Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 65: 9294-9303.
39. Reddy, KB, Nabha, SM and Atanaskova, N (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403.
40. Hynes, RO (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
41. Gjerdrum, C, Tiron, C, Høiby, T, Stefansson, I, Haugen, H, Sandal, T et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107: 1124-1129.
42. Thiery, JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
43. Singh, SK, Clarke, ID, Terasaki, M, Bonn, VE, Hawkins, C, Squire, J et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
44. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
45. Yeh, CY, Shin, SM, Yeh, HH, Wu, TJ, Shin, JW, Chang, TY et al. (2011). Transcriptional activation of the Axl and PDGFR-a by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 11: 139.
46. Schmidt, T, Ben-Batalla, I, Schultze, A and Loges, S (2012). Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. Cell Mol Life Sci 69: 1391-1414.
47. Keefe, AD, Pai, S and Ellington, A (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
48. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
49. Thiel, KW and Giangrande, PH (2010). Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 1: 849-861.
50. Zhou, J and Rossi, JJ (2010). Aptamer-targeted cell-specific RNA interference. Silence 1: 4.